Cargando…

P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate

Prostate smooth muscle tone and hyperplastic growth are involved in the pathophysiology and treatment of male lower urinary tract symptoms (LUTS). Available drugs are characterized by limited efficacy. Patients’ adherence is particularly low to combination therapies of 5α-reductase inhibitors and α(...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yiming, Gratzke, Christian, Tamalunas, Alexander, Wiemer, Nicolas, Ciotkowska, Anna, Rutz, Beata, Waidelich, Raphaela, Strittmatter, Frank, Liu, Chunxiao, Stief, Christian G., Hennenberg, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829229/
https://www.ncbi.nlm.nih.gov/pubmed/27071060
http://dx.doi.org/10.1371/journal.pone.0153312
_version_ 1782426720316424192
author Wang, Yiming
Gratzke, Christian
Tamalunas, Alexander
Wiemer, Nicolas
Ciotkowska, Anna
Rutz, Beata
Waidelich, Raphaela
Strittmatter, Frank
Liu, Chunxiao
Stief, Christian G.
Hennenberg, Martin
author_facet Wang, Yiming
Gratzke, Christian
Tamalunas, Alexander
Wiemer, Nicolas
Ciotkowska, Anna
Rutz, Beata
Waidelich, Raphaela
Strittmatter, Frank
Liu, Chunxiao
Stief, Christian G.
Hennenberg, Martin
author_sort Wang, Yiming
collection PubMed
description Prostate smooth muscle tone and hyperplastic growth are involved in the pathophysiology and treatment of male lower urinary tract symptoms (LUTS). Available drugs are characterized by limited efficacy. Patients’ adherence is particularly low to combination therapies of 5α-reductase inhibitors and α(1)-adrenoceptor antagonists, which are supposed to target contraction and growth simultaneously. Consequently, molecular etiology of benign prostatic hyperplasia (BPH) and new compounds interfering with smooth muscle contraction or growth in the prostate are of high interest. Here, we studied effects of p21-activated kinase (PAK) inhibitors (FRAX486, IPA3) in hyperplastic human prostate tissues, and in stromal cells (WPMY-1). In hyperplastic prostate tissues, PAK1, -2, -4, and -6 may be constitutively expressed in catecholaminergic neurons, while PAK1 was detected in smooth muscle and WPMY-1 cells. Neurogenic contractions of prostate strips by electric field stimulation were significantly inhibited by high concentrations of FRAX486 (30 μM) or IPA3 (300 μM), while noradrenaline- and phenylephrine-induced contractions were not affected. FRAX486 (30 μM) inhibited endothelin-1- and -2-induced contractions. In WPMY-1 cells, FRAX486 or IPA3 (24 h) induced concentration-dependent (1–10 μM) degeneration of actin filaments. This was paralleled by attenuation of proliferation rate, being observed from 1 to 10 μM FRAX486 or IPA3. Cytotoxicity of FRAX486 and IPA3 in WPMY-1 cells was time- and concentration-dependent. Stimulation of WPMY-1 cells with endothelin-1 or dihydrotestosterone, but not noradrenaline induced PAK phosphorylation, indicating PAK activation by endothelin-1. Thus, PAK inhibitors may inhibit neurogenic and endothelin-induced smooth muscle contractions in the hyperplastic human prostate, and growth of stromal cells. Targeting prostate smooth muscle contraction and stromal growth at once by a single compound is principally possible, at least under experimental conditions.
format Online
Article
Text
id pubmed-4829229
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48292292016-04-22 P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate Wang, Yiming Gratzke, Christian Tamalunas, Alexander Wiemer, Nicolas Ciotkowska, Anna Rutz, Beata Waidelich, Raphaela Strittmatter, Frank Liu, Chunxiao Stief, Christian G. Hennenberg, Martin PLoS One Research Article Prostate smooth muscle tone and hyperplastic growth are involved in the pathophysiology and treatment of male lower urinary tract symptoms (LUTS). Available drugs are characterized by limited efficacy. Patients’ adherence is particularly low to combination therapies of 5α-reductase inhibitors and α(1)-adrenoceptor antagonists, which are supposed to target contraction and growth simultaneously. Consequently, molecular etiology of benign prostatic hyperplasia (BPH) and new compounds interfering with smooth muscle contraction or growth in the prostate are of high interest. Here, we studied effects of p21-activated kinase (PAK) inhibitors (FRAX486, IPA3) in hyperplastic human prostate tissues, and in stromal cells (WPMY-1). In hyperplastic prostate tissues, PAK1, -2, -4, and -6 may be constitutively expressed in catecholaminergic neurons, while PAK1 was detected in smooth muscle and WPMY-1 cells. Neurogenic contractions of prostate strips by electric field stimulation were significantly inhibited by high concentrations of FRAX486 (30 μM) or IPA3 (300 μM), while noradrenaline- and phenylephrine-induced contractions were not affected. FRAX486 (30 μM) inhibited endothelin-1- and -2-induced contractions. In WPMY-1 cells, FRAX486 or IPA3 (24 h) induced concentration-dependent (1–10 μM) degeneration of actin filaments. This was paralleled by attenuation of proliferation rate, being observed from 1 to 10 μM FRAX486 or IPA3. Cytotoxicity of FRAX486 and IPA3 in WPMY-1 cells was time- and concentration-dependent. Stimulation of WPMY-1 cells with endothelin-1 or dihydrotestosterone, but not noradrenaline induced PAK phosphorylation, indicating PAK activation by endothelin-1. Thus, PAK inhibitors may inhibit neurogenic and endothelin-induced smooth muscle contractions in the hyperplastic human prostate, and growth of stromal cells. Targeting prostate smooth muscle contraction and stromal growth at once by a single compound is principally possible, at least under experimental conditions. Public Library of Science 2016-04-12 /pmc/articles/PMC4829229/ /pubmed/27071060 http://dx.doi.org/10.1371/journal.pone.0153312 Text en © 2016 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wang, Yiming
Gratzke, Christian
Tamalunas, Alexander
Wiemer, Nicolas
Ciotkowska, Anna
Rutz, Beata
Waidelich, Raphaela
Strittmatter, Frank
Liu, Chunxiao
Stief, Christian G.
Hennenberg, Martin
P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate
title P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate
title_full P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate
title_fullStr P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate
title_full_unstemmed P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate
title_short P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate
title_sort p21-activated kinase inhibitors frax486 and ipa3: inhibition of prostate stromal cell growth and effects on smooth muscle contraction in the human prostate
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829229/
https://www.ncbi.nlm.nih.gov/pubmed/27071060
http://dx.doi.org/10.1371/journal.pone.0153312
work_keys_str_mv AT wangyiming p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT gratzkechristian p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT tamalunasalexander p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT wiemernicolas p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT ciotkowskaanna p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT rutzbeata p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT waidelichraphaela p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT strittmatterfrank p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT liuchunxiao p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT stiefchristiang p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate
AT hennenbergmartin p21activatedkinaseinhibitorsfrax486andipa3inhibitionofprostatestromalcellgrowthandeffectsonsmoothmusclecontractioninthehumanprostate